Table 1 Clinical characteristics of the Nordic JIA study population
Characteristics | Total no. assessed | Values |
|---|---|---|
Female sex, no. (%) | 377 | 271 (72) |
Age at disease onset, years, median (IQR) | 377 | 5.6 (2.6–9.7) |
Age at 18-year follow-up, years, median (IQR) | 377 | 23.3 (20.2–27.1) |
Disease duration at 18-year follow-up, years, median (IQR) | 375 | 17.5 (16.8–18.3) |
Oligoarticular JIA at onset, no. (%) | 377 | 201 (53) |
Oligoarticulara JIA at 18-year follow-up, no. (%) | 377 | 175 (46) |
VAS pain at 18-year follow-up, mean (±SD) | 370 | 1.9 (±2.4) |
SF-36 PCS at 18-year follow-up, mean (±SD) | 377 | 51.5 (±9.7) |
SF-36 MCS at 18-year follow-up, mean (±SD) | 377 | 49.1 (±11.3) |
HAQ at 18-year follow-up, mean (±SD) | 370 | 0.2 (±0.4) |
Not in remissionb at 18-year follow-up (visits), no. (%) | 308 | 196 (63) |
Not in remissionb at 18-year follow-up (visits/telephonec), no. (%) | 369 | 215 (58) |
DMARDs and/or biologics ongoing at 18-year follow-up, no. (%) | 377 | 118 (31) |
DMARDs and/or biologics ever during disease course, no. (%) | 377 | 239 (63) |